363 related articles for article (PubMed ID: 32301022)
1. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
4. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
[TBL] [Abstract][Full Text] [Related]
6. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity danger in immunotherapy.
Jagielska B; Ozdowska P; Gepner K; Kubala S; Siedlecki JA; Sarnowski TJ; Sarnowska E
IUBMB Life; 2020 Jun; 72(6):1160-1167. PubMed ID: 32359132
[TBL] [Abstract][Full Text] [Related]
8. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
11. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicities of novel cancer immunotherapies.
Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
[TBL] [Abstract][Full Text] [Related]
13. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
15. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
Gutierrez C; Rajendram P; Pastores SM
Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management.
Eftekhar SP; Yazdanpanah N; Rezaei N
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1211-1228. PubMed ID: 34511008
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-Associated Myocarditis.
Spisarová M
Klin Onkol; 2020; 33(1):20-22. PubMed ID: 32075384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
